AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT00635414
Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6268
- Registration Number
- NCT00634400
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added)
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 597
- Registration Number
- NCT00634309
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 734
- Registration Number
- NCT00634712
CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: exenatideDrug: any human insulin or analog insulin(s) given in any regimen by subcutaneous injection
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2015-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2515
- Registration Number
- NCT00635492
- Locations
- 🇸🇪
Research Site, Vastervik, Sweden
🇩🇪Research, Birkenfeld, Germany
A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued in Subjects in the US Only
Phase 3
Completed
- Conditions
- NSAID Associated Gastric Ulcers
- Interventions
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2009-06-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT00633412
Canadian, Multi-Centre Study of Symptom Burden and Clinical Management in Subjects With GERD
Completed
- Conditions
- GERD
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2009-03-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT00634023
- Locations
- 🇨🇦
Research Site, Woodstock, Ontario, Canada
Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours
Phase 1
Completed
- Conditions
- Neoplasm Metastasis
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2009-01-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT00633269
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued
Phase 3
Completed
- Conditions
- NSAID Associated Gastric Ulcers
- Interventions
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT00633672
Reflux Esophagitis Phase III Study (Initial Treatment)
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2010-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 602
- Registration Number
- NCT00633932
- Locations
- 🇯🇵
Research Site, Tottori, Japan
© Copyright 2025. All Rights Reserved by MedPath